Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy
Abstract Background Indoleamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenine, an immunosuppressive metabolite involved in T regulatory cell differentiation. Indoleamine 2,3-dioxygenase is expressed in many cancer types, including breast cancer. Here, we analyze kynurenine and...
Main Authors: | Concetta Elisa Onesti, François Boemer, Claire Josse, Stephane Leduc, Vincent Bours, Guy Jerusalem |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-07-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-019-1984-2 |
Similar Items
-
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
by: Florent Peyraud, et al.
Published: (2022-01-01) -
TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01) -
The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01) -
Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
by: Pilvi Maliniemi, et al.
Published: (2017-03-01) -
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
by: Andrea Botticelli, et al.
Published: (2020-07-01)